The price at the counter can follow a different calculation
A drug’s list price is its advertised starting price, not necessarily what an insurer ultimately pays. After a sale, a manufacturer may provide a rebate negotiated by a pharmacy benefit manager, or PBM—the company that helps an insurer or employer choose covered drugs and manage prescription benefits. That rebate can reduce the plan’s net cost, but it may arrive later and be handled separately from the pharmacy transaction.
At the counter, a patient’s bill is determined by the rules of their particular insurance plan. A fixed copay may shield them from changes in the list price. But if the plan charges coinsurance—a percentage of the drug’s price—or the patient has not yet met a deductible, the bill may be calculated from a price that does not reflect the later rebate. The plan can therefore save money overall while the patient sees little or none of that saving at checkout.
Why rebates do not automatically lower every bill
PBMs negotiate rebates partly in exchange for favorable coverage, such as placing a drug on a preferred list. That can make a medicine more attractive to a plan even when its list price is high. The rebate’s destination depends on the contracts among the PBM, insurer, employer, and other parties; it is not automatically a discount applied to each prescription at the pharmacy.
This helps explain why two people filling the same insulin can face different costs, and why a rebate in the supply chain does not guarantee an affordable bill. The crucial distinction is between what the system pays after negotiations and what a patient’s plan asks them to pay at the counter.
